Results 11 to 20 of about 20,731 (163)

Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing Enterobacterales

Frontiers in Medicine, 2023
Among carbapenem-resistant Enterobacterales, metallo-beta-lactamase producing strains represent a growing therapeutic challenge. While the association of aztreonam and ceftazidime-avibactam has been investigated in recent years for the treatment of ...
Yanis Merad, Anne Conrad, Anne Conrad, Anne Conrad, Anne Conrad, Sophie Brosset, Sophie Brosset, Axel Schmidt, Axel Schmidt, Camille Hanriat, Camille Hanriat, Sebastien Lustig, Sebastien Lustig, Sebastien Lustig, Frederic Laurent, Frederic Laurent, Frederic Laurent, Frederic Laurent, Camille Kolenda, Camille Kolenda, Camille Kolenda, Camille Kolenda, Tiphaine Roussel-Gaillard, Tiphaine Roussel-Gaillard, Tiphaine Roussel-Gaillard, Cecile Batailler, Cecile Batailler, Cecile Batailler, Tristan Ferry, Tristan Ferry, Tristan Ferry, Tristan Ferry, Lyon BJI Study group   +32 more
doaj   +1 more source

Evaluation of Aztreonam and Ceftazidime/Avibactam Synergism against Klebsiella pneumoniae by MALDI-TOF MS

Antibiotics, 2023
Introduction: Resistance to carbapenems due to the co-production of NDM and ESBL or NDM and KPC is increasing. Therefore, combined therapy with aztreonam (ATM) plus ceftazidime/avibactam (CZA) has been recommended.
Camila Mörschbächer Wilhelm, Everton Inamine, Andreza Francisco Martins, Afonso Luís Barth   +3 more
doaj   +1 more source

Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections

Antibiotics, 2021
Metallo-β-lactamases (MBLs) are among the most challenging bacterial enzymes to overcome. Aztreonam (ATM) is the only β-lactam not hydrolyzed by MBLs but is often inactivated by co-produced extended-spectrum β-lactamases (ESBL).
Gianluca Morroni, Raffaela Bressan, Simona Fioriti, Gloria D’Achille, Marina Mingoia, Oscar Cirioni, Stefano Di Bella, Aurora Piazza, Francesco Comandatore, Carola Mauri, Roberta Migliavacca, Francesco Luzzaro, Luigi Principe, Cristina Lagatolla   +13 more
doaj   +1 more source

Experimental Design Supported Liposomal Aztreonam Delivery: In Vitro Studies [PDF]

Advanced Pharmaceutical Bulletin, 2021
Purpose: The present study focuses on a systemic approach to develop liposomal aztreonam as a promising dosage form for inhalation therapy in the treatment of pneumonia and explores the in-vitro antimicrobial and cell uptake efficacy.
Sayani Bhattacharyya, Preethi Sudheer, Kuntal Das, Subhabrata Ray   +3 more
doaj   +1 more source

Comparative metabolomics reveal key pathways associated with the synergistic activities of aztreonam and clavulanate combination against multidrug-resistant Escherichia coli

mSystems, 2023
The use of combination antibiotics has been useful in the treatment of multidrug-resistant bacterial infections. The synergistic effect of amoxicillin/clavulanate and aztreonam combination against Escherichia coli carrying New Delhi metallo-β-lactamase ...
Jiayuan Zhang, Hai Yang, Lei Zhang, Zhihua Lv, Mingming Yu, Sherwin K. B. Sy, Yuanchao Zhan   +6 more
doaj   +1 more source

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020

Antibiotics, 2023
Increasing antimicrobial resistance among multidrug-resistant (MDR), extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing Enterobacterales (CPE), in particular metallo-β-lactamase (MBL)-positive strains, has led to limited treatment options ...
Denis Piérard, Elizabeth D. Hermsen, Michal Kantecki, Francis F. Arhin   +3 more
doaj   +1 more source

Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in Pseudomonas aeruginosa

mBio, 2017
While much attention has been focused on acquired antibiotic resistance genes, chromosomal mutations may be most important in chronic infections where isolated, persistently infecting lineages experience repeated antibiotic exposure.
Peter Jorth, Kathryn McLean, Anina Ratjen, Patrick R. Secor, Gilbert E. Bautista, Sumedha Ravishankar, Amir Rezayat, Jayanthi Garudathri, Joe J. Harrison, Rachel A. Harwood, Kelsi Penewit, Adam Waalkes, Pradeep K. Singh, Stephen J. Salipante   +13 more
doaj   +1 more source

The First Experience of Combined Use of Cefepime/Sulbactam and Aztreonam in ICU Patients with Nosocomial Infections Caused by Carbapenem-Resistant Gram-Negative Microorganisms Producing Class B and D Carbapenemases

Антибиотики и Химиотерапия, 2023
Background. The difficulties of antibacterial therapy of infections caused by carbapenemase-producing  gram-negative bacteria are associated with limited options for adequate therapy since, in addition to resistance to carbapenems and other beta-lactams ...
M. P. Suvorova, I. N. Sychev, O. V. Ignatenko, E. N. Burmistrova, S. S. Mirzakhamidova, L. V. Fedina, R. M. Vakolyuk, S. V. Yakovlev   +7 more
doaj   +1 more source

Aztreonam

Medical Clinics of North America, 1995
Aztreonam is a monocyclic beta-lactam antibiotic that is active exclusively against the aerobic gram-negative bacilli. It is not ototoxic or nephrotoxic and so is used as an alternative to aminoglycosides in a variety of clinical situations.
D H, Johnson, B A, Cunha
openaire   +2 more sources

The phenomenon of changing aztreonam susceptibility in Pseudomonas aeruginosa during formation of colistin resistance in vitro [PDF]

Клиническая микробиология и антимикробная химиотерапия
Objective. To describe the phenotypic and genome characteristics of the phenomenon of aztreonam susceptibility changes in a clinical Pseudomonas aeruginosa isolate developing colistin resistance in an evolutionary experiment in vivo.
Bocharova Yu.A., Kuleshov K.V., Chebotar I.V., Mayanskiy N.A.   +3 more
doaj   +1 more source